Patient has hypersensitivity to boron, mannitol sucrose, histidine (as base and hydrochloride salt) and polysorbate 80 or any of the components of study therapy including required prophylactic medications
Patients with hypersensitivity to bortezomib, boron or mannitol.
Known hypersensitivity to Velcade, boron, or mannitol
Known or suspected hypersensitivity to 5-azacitidine or mannitol
Known or suspected hypersensitivity to azacitidine or mannitol
Known hypersensitivity to azacitidine or mannitol
Have a history of allergic (anaphylactic) sensitivity to bortezomib, boron or mannitol
History of allergy to mannitol
History of hypersensitivity to mannitol
Subjects must not have a known history of hypersensitivity to mannitol
Must not have a known or suspected hypersensitivity to azacitidine, mannitol, or compounds of similar composition to azacitidine
Patient with hypersensitivity to bortezomib, boron or dexamethasone
Patient has hypersensitivity to bortezomib, boron, or mannitol
Known hypersensitivity to any of the following: bortezomib, boron, mannitol
Known allergy or hypersensitivity to azacitidine, mannitol, or midostaurin
Previous history of hypersensitivity to bortezomib, boron, or mannitol; known hypersensitivity to the components of study drug or its analogs
Patient has hypersensitivity to VELCADE (bortezomib), boron, or mannitol
Participant who has hypersensitivity to bortezomib, boron, or mannitol
Known intolerance/hypersensitivity to IMiDs, dexamethasone, boron or mannitol, sucrose, histidine or polysorbate 80.
Known or suspected hypersensitivity to azacitidine or mannitol
Known or suspected hypersensitivity to azacitidine, mannitol, or durvalumab, its constituents, or to any other humanized monoclonal antibody.
Patient has hypersensitivity to bortezomib, boron or mannitol
Known hypersensitivity to mannitol.
Has a known hypersensitivity to azacitidine or mannitol
Patients with known allergy to sorafenib or azacitidine, mannitol or any of their components
Patients must not have a known allergy to mannitol
Patient has hypersensitivity to VELCADE (bortezomib), boron, or mannitol
Patients must not have hypersensitivity to bortezomib, boron or mannitol
Participant has a known or suspected hypersensitivity to azacitidine, mannitol, or any other ingredient used in the manufacture of CC-486 (see the Azacitidine IB).
History of allergic reaction/hypersensitivity attributed to compounds containing boron, mannitol, polysorbate 80 or sodium citrate dehydrate
Patient has hypersensitivity to bortezomib, boron, or mannitol
Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to dexamethasone, boron or mannitol
Known or suspected hypersensitivity to azacitidine or mannitol
Known hypersensitivity to bortezomib, boron, or mannitol
History of allergy to mannitol
Known allergy to bortezomib, boron, or mannitol
Known hypersensitivity to bortezomib, boron, or any of the other agents utilized in this protocol
Patient has hypersensitivity to bortezomib, boron, or mannitol
Known or suspected hypersensitivity to 5-azacitidine, romidepsin, mannitol or other agents used in this study
Hypersensitivity to boron or mannitol, or compounds containing these components
Patient has hypersensitivity to bortezomib, boron or mannitol
History of allergic reactions to compounds containing boron, mannitol, VELCADE
Known hypersensitivity to any components of pracinostat, azacitidine, or mannitol
History of sensitivity to mannitol
Hypersensitivity to bortezomib, boron, or mannitol
Known or suspected hypersensitivity to azacitidine or mannitol
No history of hypersensitivity to bortezomib, boron or mannitol
Patient has hypersensitivity to bortezomib, boron, or mannitol
Known hypersensitivity to mannitol
Known hypersensitivity to bendamustine or mannitol
Patient has hypersensitivity to bortezomib, boron, or mannitol
Known hypersensitivity to azacitidine or mannitol
Known or suspected hypersensitivity to azacitidine or mannitol
Hypersensitivity to VELCADE, boron, mannitol, or any other component of protocol therapy
Known hypersensitivity to bortezomib, boron, or mannitol
Known or suspected hypersensitivity to 5'-azacitidine or mannitol
Allergy to mannitol
Patients with hypersensitivity to carfilzomib, Velcade, boron, or mannitol.
Patient has hypersensitivity to bortezomib, boron or mannitol
Patient has a history of allergic reaction attributable to bortezomib or other compounds containing boron or mannitol (Phase 1b and 2a only)
Known or suspected hypersensitivity to ofatumumab, bendamustine or mannitol.
Known hypersensitivity to bendamustine, mannitol, or other study-related drugs
Hypersensitivity to azacitidine or mannitol
Known or suspected hypersensitivity to azacitidine or mannitol
History of sensitivity to mannitol
Known or suspected hypersensitivity to azacitidine, mannitol, its constituents, or to any other humanized monoclonal antibody
Patients with hypersensitivity to bortezomib, boron or mannitol
Patients with hypersensitivity to bortezomib, boron or mannitol
Known or suspected hypersensitivity to azacitidine, pembrolizumab or the excipients of any of the study drugs (including mannitol). Known or suspected hypersensitivity to monoclonal antibodies.
